Growth Metrics

Avadel Pharmaceuticals (AVDL) EBIT Margin: 2009-2020

Historic EBIT Margin for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2020 value amounting to 26.04%.

  • Avadel Pharmaceuticals' EBIT Margin rose 49790.00% to 431.08% in Q4 2020 from the same period last year, while for Dec 2020 it was 36.88%, marking a year-over-year increase of 7760.00%. This contributed to the annual value of 26.04% for FY2020, which is 6676.00% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported EBIT Margin of 26.04% as of FY2020, which was up 163.94% from -40.72% recorded in FY2019.
  • Avadel Pharmaceuticals' 5-year EBIT Margin high stood at 51.66% for FY2017, and its period low was -101.60% during FY2018.
  • Its 3-year average for EBIT Margin is -38.76%, with a median of -40.72% in 2019.
  • Per our database at Business Quant, Avadel Pharmaceuticals' EBIT Margin slumped by 15,327bps in 2018 and then soared by 6,676bps in 2020.
  • Yearly analysis of 5 years shows Avadel Pharmaceuticals' EBIT Margin stood at -3.30% in 2016, then skyrocketed by 5,497bps to 51.66% in 2017, then slumped by 15,327bps to -101.60% in 2018, then spiked by 6,089bps to -40.72% in 2019, then spiked by 6,676bps to 26.04% in 2020.